keyword
MENU ▼
Read by QxMD icon Read
search

Risperdal consta

keyword
https://www.readbyqxmd.com/read/26423236/in-vitro-in-vivo-correlation-of-parenteral-risperidone-polymeric-microspheres
#1
Jie Shen, Stephanie Choi, Wen Qu, Yan Wang, Diane J Burgess
The objective of the present study was to determine whether an in vitro-in vivo correlation (IVIVC) can be established for polymeric microspheres that are equivalent in formulation composition but prepared with different manufacturing processes. Risperidone was chosen as a model therapeutic and poly(lactic-co-glycolic acid) (PLGA) with similar molecular weight as that used in the commercial product Risperdal® Consta® was used to prepare risperidone microspheres. Various manufacturing processes were investigated to produce the risperidone microspheres with similar drug loading (approx...
November 28, 2015: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/26319639/a-protocol-for-assay-of-poly-lactide-co-glycolide-in-clinical-products
#2
John Garner, Sarah Skidmore, Haesun Park, Kinam Park, Stephanie Choi, Yan Wang
Poly(lactide-co-glycolide) (PLGA) is the key component of long acting drug products responsible for providing sustained release in a controlled manner. The objective of the current study was to develop and validate an analytical protocol to determine key properties of PLGA used in commercial long-acting drug products. Procedures to isolate PLGA from commercial products have been established and the key properties of PLGA, such as polymer molecular weight, lactide:glycolide (L:G) ratio, and nature of polymer end-cap, have been determined...
November 10, 2015: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/25709335/development-of-a-novel-3-month-drug-releasing-risperidone-microspheres
#3
Bhanusree Yerragunta, Satheesh Jogala, Krishna Mohan Chinnala, Jithan Aukunuru
OBJECTIVE: The purpose of this study was to develop an ideal microsphere formulation of risperidone that would prolong the drug release for 3 months in vivo and avoid the need for co-administration of oral tablets. MATERIALS AND METHODS: Polycaprolactones (PCL) were used as polymers to prepare microspheres. The research included screening and optimizing of suitable commercial polymers of variable molecular weights: PCL-14000, PCL-45000, PCL-80000 or the blends of these polymers to prepare microspheres with zero-order drug-releasing properties without the lag phase...
January 2015: Journal of Pharmacy & Bioallied Sciences
https://www.readbyqxmd.com/read/25043337/population-pharmacokinetic-modeling-and-simulation-to-guide-dose-selection-for-rbp-7000-a-new-sustained-release-formulation-of-risperidone
#4
RANDOMIZED CONTROLLED TRIAL
Celine M Laffont, Roberto Gomeni, Bo Zheng, Christian Heidbreder, Paul J Fudala, Azmi F Nasser
RBP-7000 is a long-acting formulation of risperidone designed for once-monthly subcutaneous injection for the treatment of schizophrenia. The objective was to estimate clinically effective doses of RBP-7000 based on model simulations and on the comparison with other long-acting injectable antipsychotics. A population pharmacokinetic model of RBP-7000 was developed in 90 clinically stable schizophrenic patients having received single/repeated doses of 60, 90, or 120 mg. Model simulations were conducted to compare active moiety plasma exposure after repeated RBP-7000 administrations to the published data of long-acting risperidone injection (Risperdal® Consta®) at 25 and 50 mg, and of paliperidone palmitate (Invega® Sustenna®) at 50 and 100 mg equivalent paliperidone...
January 2015: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/24630262/a-six-month-randomized-controlled-trial-of-long-acting-injectable-risperidone-50-and-100mg-in-treatment-resistant-schizophrenia
#5
RANDOMIZED CONTROLLED TRIAL
H Y Meltzer, J-P Lindenmayer, J Kwentus, D B Share, R Johnson, K Jayathilake
It has been suggested that atypical antipsychotic drugs (A-APDs) other than clozapine may be effective to improve positive symptoms in some patients with treatment resistant schizophrenia (TRS), if both the dose is higher, and the duration of the trial longer, than those which have been ineffective in non-TRS (NTRS) patients. This hypothesis was tested with long acting injectable risperidone (Risperdal Consta®, RLAI). One hundred sixty TRS patients selected for persistent moderate-severe delusions or hallucinations, or both, were randomized to RLAI, 50 or 100mg biweekly, in a six month, outpatient, double-blind, multicenter trial...
April 2014: Schizophrenia Research
https://www.readbyqxmd.com/read/23892159/microsphere-delivery-of-risperidone-as-an-alternative-to-combination-therapy
#6
COMPARATIVE STUDY
Susan D'Souza, Jabar Faraj, Patrick DeLuca
The purpose of this study was to develop a parenteral delivery system of Risperidone that would provide initial and extended drug release and thereby avoid the need for co-administration of oral tablets. Key formulation parameters utilized to achieve desired therapeutic levels in vivo were particle size and drug loading. Three poly (D,L-lactide-co-glycolide) (PLGA) microsphere formulations (Formulations A, B, and C) that encapsulated Risperidone were prepared by varying particle size (19-49 μm) and drug loading parameters (31-37%) but with a uniform bulk density (0...
November 2013: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/23808900/economic-and-clinical-comparison-of-atypical-depot-antipsychotic-drugs-for-treatment-of-chronic-schizophrenia-in-the-czech-republic
#7
COMPARATIVE STUDY
Thomas R Einarson, Roman Zilbershtein, Jana Skoupá, Sárka Veselá, Madhur Garg, Michiel E H Hemels
PURPOSE: The Czech Republic is faced with making choices between pharmaceutical products, including depot injectable antipsychotics. A pharmacoeconomic analysis was conducted to determine the cost-effectiveness of atypical depots. METHODS: An existing 1-year decision-analytic framework was adapted to model drug use in this healthcare system. The average direct costs to the General Insurance Company of the Czech Republic of using paliperidone palmitate (Xeplion®), risperidone (Risperdal Consta®), and olanzapine pamoate (Zypadhera®) were determined...
September 2013: Journal of Medical Economics
https://www.readbyqxmd.com/read/22966099/second-generation-long-acting-injectable-antipsychotic-agents-an-overview
#8
REVIEW
(no author information available yet)
For over 40 years, antipsychotic drugs have been used as long-term maintenance treatment to control symptoms and reduce relapse rates in patients with schizophrenia. 'First-generation' oral agents such as haloperidol and chlorpromazine are associated with high levels of unwanted neurological effects and poor rates of patient adherence.1,2 Long-acting ('depot') injections of antipsychotics were developed to try to improve adherence. 'Second-generation' antipsychotic agents (also known as atypical antipsychotics) were introduced into clinical practice over 16 years ago...
September 2012: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/22659126/comparison-of-in-vitro-in-vivo-release-of-risperdal-%C3%A2-consta-%C3%A2-microspheres
#9
Archana Rawat, Upkar Bhardwaj, Diane J Burgess
The objective was to investigate the relationship between in vitro and in vivo release of commercial Risperdal(®) Consta(®) microspheres. A modified USP apparatus 4 method was used for accelerated and real-time in vitro release testing. The in vivo plasma profile (clinical data) reported for the product was deconvoluted for comparison with the in vitro release profiles. The in vivo profile differed from the real-time in vitro profile and was faster initially and then slower after approximately 30 days. This effect is considered to be due to differences in the in vivo conditions such as small interstitial volume, low pH and immune response...
September 15, 2012: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/22595365/mechanistic-investigations-on-the-etiology-of-risperdal-%C3%A2-consta-%C3%A2-induced-bone-changes-in-female-wistar-hannover-rats
#10
Eric J de Waal, Wendy Roosen, Petra Vinken, John Vandenberghe, Patrick Sterkens, Lieve Lammens
RISPERDAL(®) CONSTA(®) is a long-acting, intramuscular formulation of risperidone microspheres for the biweekly treatment of schizophrenia and other psychiatric disorders. In a 24-month carcinogenicity study male and female Wistar Hannover rats received RISPERDAL(®) CONSTA(®) by intramuscular injection at dosages of 5 or 40 mg/kg once every 2 weeks. Bone changes described as "osteodystrophy" were observed by routine microscopic examination at 40 mg/kg in the sternum of female rats after 12 months, and in the sternum and stifle joint of both male and female rats after 24 months of treatment, respectively...
September 28, 2012: Toxicology
https://www.readbyqxmd.com/read/21889583/validation-of-usp-apparatus-4-method-for-microsphere-in-vitro-release-testing-using-risperdal-consta
#11
Archana Rawat, Erika Stippler, Vinod P Shah, Diane J Burgess
The current manuscript addresses the need for a validated in vitro release testing method for controlled release parenteral microspheres. A USP apparatus 4 method was validated with the objective of possible compendial adaptation for microsphere in vitro release testing. Commercial microspheres (Risperdal Consta) were used for method validation. Accelerated and real-time release tests were conducted. The accelerated method had significantly reduced test duration and showed a good correlation with the real-time release profile (with limited number of sample analysis)...
November 28, 2011: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/20977322/risperidone-long-acting-injectable-risperdal-consta%C3%A2-for-maintenance-treatment-in-patients-with-bipolar-disorder
#12
REVIEW
William V Bobo, Richard C Shelton
Poor adherence to pharmacotherapy during maintenance-phase treatment of bipolar disorder is a common occurrence, exposing patients to a high risk of illness relapses, rehospitalization and other negative outcomes. In view of this, there has been a reawakening of interest in the potential of long-acting injectable antipsychotic medications to improve treatment outcome during bipolar maintenance therapy. Indeed, long-acting injectable medications have practical advantages of assuring delivery of medication at a prescribed dose, and perhaps also making it easier to monitor adherence, at least to the long-acting drug...
November 2010: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/20370594/biodegradable-poly-d-l-lactide-co-glycolide-plga-microspheres-for-sustained-release-of-risperidone-zero-order-release-formulation
#13
Zheng-Xing Su, Ya-Nan Shi, Le-Sheng Teng, Xiang Li, Le-xi Wang, Qing-Fan Meng, Li-Rong Teng, You-Xin Li
The preparation and investigation of sustained-release risperidone-encapsulated microspheres using erodible poly(D, L-lactide-co-glycolide) (PLGA) of lower molecular weight were performed and compared to that of commercial Risperdal Consta™ for the treatment of schizophrenia. The research included screening and optimizing of suitable commercial polymers of lower molecular weight PLGA50/50 or the blends of these PLGA polymers to prepare microspheres with zero-order release kinetics properties. Solvent evaporation method was applied here while studies of the risperidone loaded microsphere were carried out on its drug encapsulation capacity, morphology, particle size, as well as in vitro release profiles...
August 2011: Pharmaceutical Development and Technology
https://www.readbyqxmd.com/read/20099224/prospective-open-study-of-long-acting-injected-risperidone-versus-oral-antipsychotics-in-88-chronically-psychotic-patients
#14
COMPARATIVE STUDY
P Girardi, G Serafini, M Pompili, M Innamorati, R Tatarelli, R J Baldessarini
INTRODUCTION: A long-acting, injected, carbohydrate-microsphere preparation of risperidone (RLAI; Risperdal Consta ((R))) is reported to be safe and effective in chronic psychotic illnesses but, as its long-term and comparative efficacy remain unclear, this study compared clinical status during oral antipsychotic treatment versus conversion to RLAI. METHODS: Psychotic patients (n=88; initial BPRS=93+/-5) were treated for 6 months with clinically chosen oral medication and then converted to biweekly RLAI for the first 6 months (6-6 months matched mirror comparison) and then for another 18 months...
March 2010: Pharmacopsychiatry
https://www.readbyqxmd.com/read/20084535/the-impact-on-schizophrenia-related-hospital-utilization-and-costs-of-switching-to-long-acting-risperidone-injections-in-sweden
#15
Michael Willis, Marianne Svensson, Mickael Löthgren, Bo Eriksson, Anders Berntsson, Ulf Persson
AIM: To estimate changes in resource usage, hospitalization rates, and costs in actual practice in Sweden for schizophrenia patients after switching to long-acting injectable risperidone (Risperdal Consta). METHODS: A retrospective chart review within-subject mirror-image study using actual practice chart review data was used to compare annual hospital bed-days and annual hospital episodes for adults with schizophrenia or schizoaffective disorder before and after switching to Risperdal Consta in the period 1 January 2003 to 30 June 2005...
December 2010: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/19831836/experience-with-injectable-long-acting-risperidone-in-long-term-therapy-after-an-acute-episode-of-schizophrenia-the-sphere-study
#16
MULTICENTER STUDY
Jesús De la Gándara, Luis San Molina, Gabriel Rubio, Alexander Rodriguez-Morales, Rebeca Hidalgo Borrajo, José Antonio Burón
BACKGROUND: Risperidone long-acting injectable (RLAI) is the first long-acting formulation of an atypical antipsychotic introduced into clinical practice. RLAI combines the benefits of atypical antipsychotic agents with an extended duration of activity and is intended for long-term management of schizophrenia. This study evaluated the use of RLAI as part of a long-term management strategy in patients with an acute episode of schizophrenia. OBJECTIVES: The primary objective was to determine clinicians' approaches to the use of RLAI in patients with an acute exacerbation of schizophrenia by examining the prescribing patterns of antipsychotic and other psychotropic medications...
October 2009: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/19102665/use-of-long-acting-risperidone-in-psychiatric-disorders-focus-on-efficacy-safety-and-cost-effectiveness
#17
REVIEW
Samuel Keith
Schizophrenia is a chronic disorder, usually necessitating lifelong treatment. Although atypical antipsychotic agents have improved outcomes in schizophrenia, their clinical potential remains limited by patients' nonadherence to medication. Long-acting antipsychotics were developed in the 1960s to enhance treatment adherence and simplify the medication process. However, although conventional long-acting agents assure medication delivery, they are associated with similar side effects to their oral equivalents...
January 2009: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/15933482/minimal-injection-site-pain-and-high-patient-satisfaction-during-treatment-with-long-acting-risperidone
#18
RANDOMIZED CONTROLLED TRIAL
Jean-Pierre Lindenmayer, Kathleen Jarboe, Cynthia A Bossie, Young Zhu, Angelika Mehnert, Robert Lasser
Long-acting injectable antipsychotic formulations of conventional antipsychotics were developed to address the problem of partial adherence among patients with schizophrenia. Injection site pain, other skin reactions and patient satisfaction with treatment were assessed in two large, multicentre studies of long-acting injectable risperidone (Risperdal CONSTA, Janssen Pharmaceutica Products, Titusville, New Jersey, USA), the first available long-acting atypical antipsychotic agent. Patients rated injection site pain using a 100-mm Visual Analogue Scale (VAS), and investigators rated injection site pain, redness, swelling and induration...
July 2005: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/15710053/pharmacokinetics-and-d2-receptor-occupancy-of-long-acting-injectable-risperidone-risperdal-consta-in-patients-with-schizophrenia
#19
MULTICENTER STUDY
Ola Gefvert, Bo Eriksson, Per Persson, Lars Helldin, Annika Björner, Erik Mannaert, Bart Remmerie, Mariëlle Eerdekens, Svante Nyberg
Thirteen patients with schizophrenia received injections of 25, 50, or 75 mg of long-acting risperidone every 2 wk. Brain D2 receptor occupancy was assessed with [11C]raclopride 2 wk after the last (fifth) injection (day 71) in seven subjects and 2 wk after the third injection (day 44) in one subject. Stable plasma concentrations were reached after the third injection and steady-state concentrations of the active moiety (risperidone + 9-hydroxyrisperidone) after the fourth injection. Steady-state plasma concentrations were maintained for 4-5 wk after the last injection and then declined rapidly...
March 2005: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/15524095/-a-long-acting-second-generation-anti-psychotic-experience-in-israel
#20
Orit Stein-Reisner, Olga Preisman, Susana Alfici, Yuval Melamed, Avi Bleich
Schizophrenia is a chronic disease characterized by psychotic symptoms as well as negative symptoms such as affective flattening, social withdrawal and occupational dysfunction. Anti-psychotic medications reduce the risk of psychotic exacerbations and hospitalization. Poor compliance is common among patients with schizophrenia. Long-acting medications have such advantages as stabilizing drug levels and improving compliance. Second generation anti-psychotic medications were found to be more effective and tolerable compared to first generation drugs...
June 2004: Harefuah
keyword
keyword
23075
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"